Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia

References

• Castillo JJ, Reagan JL, Ingham RR, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36(7):868–875. doi: 10.1016/j.leukres.2011.12.020.
   PubMed Web of Science ®Google Scholar
• Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer. 2008;122(6):1418–1421. doi: 10.1002/ijc.23176.
   PubMed Web of Science ®Google Scholar
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–591. doi: 10.1038/nrc1408.
   PubMed Web of Science ®Google Scholar
• De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546–291511. doi: 10.1155/2013/291546.
   PubMedGoogle Scholar
• Orgel E, Genkinger JM, Aggarwal D, et al. Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr. 2016;103(3):808–817. doi: 10.3945/ajcn.115.124586.
   PubMed Web of Science ®Google Scholar
• Ethier MC, Alexander S, Abla O, et al. Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(9):1677–1681. doi: 10.3109/10428194.2012.664843.
   PubMed Web of Science ®Google Scholar
• Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25(15):2063–2069. doi: 10.1200/JCO.2006.07.7792.
   PubMed Web of Science ®Google Scholar
• Gelelete CB, Pereira SH, Azevedo AM, et al. Overweight as a prognostic factor in children with acute lymphoblastic leukemia. Obesity. 2011; 19(9):1908–1911. doi: 10.1038/oby.2011.195.
   PubMed Web of Science ®Google Scholar
• Amankwah EK, Saenz AM, Hale GA, et al. Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis. Leuk Lymphoma. 2016;57(5):1140–1148. doi: 10.3109/10428194.2015.1076815.
   PubMed Web of Science ®Google Scholar
• Egnell C, Ranta S, Banerjee J, et al. Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to nordic treatment protocols. Eur J Haematol. 2020 Dec;105(6):797–807. doi: 10.1111/ejh.13517.
   PubMed Web of Science ®Google Scholar
• Wieduwilt MJ, Stock W, Advani A, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021;35(7):2076–2085. doi: 10.1038/s41375-021-01213-5.
   PubMed Web of Science ®Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–1559. doi: 10.1182/blood-2018-10-881961.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol. 2020;38(17):1897–1905. doi: 10.1200/JCO.19.03024.
   PubMed Web of Science ®Google Scholar
• Gottschalk Hojfeldt S, Grell K, Abrahamsson J, et al. Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2020;137(17):2373–2382. doi: 10.1182/blood.2020006583.
   Web of Science ®Google Scholar
• Eissa HM, Zhou Y, Panetta JC, et al. The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia. Blood Cancer J. 2017;7(2):e531–e531. doi: 10.1038/bcj.2017.11.
   PubMedGoogle Scholar
• Denton CC, Rawlins YA, Oberley MJ, et al. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018;65(3):e26891. doi: 10.1002/pbc.26891.
   Web of Science ®Google Scholar
• Hijiya N, Panetta JC, Zhou Y, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 2006;108(13):3997–4002. doi: 10.1182/blood-2006-05-024414.
   PubMed Web of Science ®Google Scholar
• Orgel E, Sposto R, Malvar J, et al. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol. 2014;32(13):1331–1337. doi: 10.1200/JCO.2013.52.6962.
   PubMed Web of Science ®Google Scholar
• Hashmi SK, Navai SA, Chambers TM, et al. Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(2):e28063.
   PubMed Web of Science ®Google Scholar
• Egnell C, Heyman M, Jonsson OG, et al. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia. Br J Haematol. 2022;196(5):1239–1247. doi: 10.1111/bjh.17936.
   PubMed Web of Science ®Google Scholar
• Duarte X, Esteves S, Neto AM, et al. Incidence and risk factors for central nervous system thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study. Br J Haematol. 2016; 174(2):280–291. doi: 10.1111/bjh.14048.
   PubMed Web of Science ®Google Scholar
• Prasca S, Carmona R, Ji L, et al. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res. 2018;165:44–50. doi: 10.1016/j.thromres.2018.02.150.
   PubMed Web of Science ®Google Scholar
• Niinimaki RA, Harila-Saari AH, Jartti AE, et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol. 200725(12):1498–1504. doi: 10.1200/JCO.2006.06.2539.
   PubMed Web of Science ®Google Scholar
• Doney K, McMillen K, Buono L, et al. Impact of body mass index on outcomes of hematopoietic stem cell transplantation in adults. Biol Blood Marrow Transplant. 2019;25(3):613–620. doi: 10.1016/j.bbmt.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Fuji S, Takano K, Mori T, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49(12):1505–1512. doi: 10.1038/bmt.2014.178.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1–253. Available online: https://apps.who.int/iris/handle/10665/42330
   Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol. 2013;90(5):404–412. doi: 10.1111/ejh.12097.
   PubMed Web of Science ®Google Scholar
• Frandsen TL, Heyman M, Abrahamsson J, et al. Complying with the European clinical trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. Eur J Cancer. 2014;50(2):251–259. doi: 10.1016/j.ejca.2013.09.027.
   PubMed Web of Science ®Google Scholar
• Raja RA, Schmiegelow K, Albertsen BK, et al. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. Br J Haematol. 2014;165(1):126–133. doi: 10.1111/bjh.12733.
   PubMed Web of Science ®Google Scholar
• Gray B. cmprsk: subdistribution Analysis of Competing Risks. R package version 2.2-7. 2014 [cited 2019 14 Dec]. Available from: https://CRAN.R-project.org/package=cmprsk.
   Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349. doi: 10.1016/j.jclinepi.2007.11.008.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021; 39(18):2037–2048. doi: 10.1200/JCO.21.00471.
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2016;96(2):160–169. doi: 10.1111/ejh.12562.
   PubMed Web of Science ®Google Scholar
• Meenan CK, Kelly JA, Wang L, et al. Obesity in pediatric patients with acute lymphoblastic leukemia increases the risk of adverse events during pre-maintenance chemotherapy. Pediatr Blood Cancer. 2019;66(2):e27515. doi: 10.1002/pbc.27515.
   PubMed Web of Science ®Google Scholar
• Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52(7):814–818. doi: 10.1002/pbc.21980.
   PubMed Web of Science ®Google Scholar
• Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018;24(4):299–308. doi: 10.1177/1078155217701291.
   PubMed Web of Science ®Google Scholar
• Biddeci G, Bosco G, Varotto E, et al. Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: early diagnosis and new treatment strategies. Anticancer Res. 2019;39(3):1259–1266. doi: 10.21873/anticanres.13236.
   PubMed Web of Science ®Google Scholar
• Stein PD, Goldman J. Obesity and thromboembolic disease. Clin Chest Med. 2009;30(3):489–493, viii. doi: 10.1016/j.ccm.2009.05.006.
   PubMed Web of Science ®Google Scholar